Results 31 to 40 of about 1,361 (136)

WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. [PDF]

Cancers (Basel)
Inhibition of WEE1, a key regulator of the G2/M checkpoint of the cell cycle, induces apoptosis by initiating mitosis without repairing DNA damage. However, the effects of WEE1 inhibitors on the tumor immune microenvironment in colorectal cancer (CRC) remain unclear.
Ariyoshi M, Yuge R, Kitadai Y, Shimizu D, Miyamoto R, Yamashita K, Hiyama Y, Takigawa H, Urabe Y, Oka S.   +9 more
europepmc   +3 more sources

Supplementary Data from Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

, 2021
Supplementary Methods, Supplementary Fig. S1 (Mean adavosertib plasma concentrations for QD vs. BID schedules), Supplementary Fig. S2 (Example PD biomarker immunofluorescence images), Supplementary Fig.
Naoko Takebe (14953338), Li Chen (5749), Abdul Rafeh Naqash (15035066), Ganesh Mugundu (10218113), Biswajit Das (15035081), Jennifer Zlott (15035075), Shivaani Kummar (107740), Ralph E. Parchment (14905824), James H. Doroshow (13270697), Deborah Wilsker (6586), Ashley Bruns (15035072), Robert J. Kinders (10881100), Larry Rubinstein (15035078), Jiuping Ji (107729), Khanh Do (1476472), Howard Streicher (3467351), Alice P. Chen (14943433), Arjun Mittra (310881), Richard Piekarz (15035022), Elad Sharon (15021041), Lamin Juwara (11100085), Ting-Chia Chang (6532961), Geraldine O'Sullivan Coyne (15035069), Sarah B. Miller (14932767)   +23 more
core   +1 more source

Data from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

, 2023
<div>AbstractPurpose:<p>Cyclin E (<i>CCNE1</i>) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted therapy.</p>Experimental Design:<p>Copy number and genomic sequencing data from The Cancer Genome Atlas and MD Anderson Cancer Center ...
Funda Meric-Bernstam, Khandan Keyomarsi, Siqing Fu, Jaffer A. Ajani, Ecaterina E. Ileana Dumbrava, Timothy A. Yap, Michael Kahle, Kathleen Kong, Bryce P. Kirby, Bailiang Wang, Xiaofeng Zheng, Yasmeen Q. Rizvi, Ming Zhao, Maria Gabriela Raso, Kurt W. Evans, Timothy P. DiPeri   +15 more
openaire   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

Tumour Cell Size Control and Its Impact on Tumour Cell Function

Cell Proliferation, Volume 58, Issue 12, December 2025.
The regulatory mechanism of the size of tumour cells and its impact on the functions of tumour cells, as well as a summary of potential therapeutic targets for the corresponding mechanisms. ABSTRACT Cell size is an important component of cell morphological characteristics.
Min Zhou, Mei Zhou, Yang Jin
wiley   +1 more source

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, Volume 3, Issue 5, September 2025.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source

The Regulation of Trace Metal Elements in Cancer Ferroptosis

Advanced Biology, Volume 9, Issue 8, August 2025.
The induction of ferroptosis inhibits tumor growth, enhances anticancer efficacy, and overcomes drug resistance. Recent evidence shows nonferrous metal elements play a role in ferroptosis. This review focuses on how trace metals regulate ferroptosis processes like iron accumulation, lipid peroxidation, and antioxidant defense.
Xiaoyan Wang, Yuanyuan Xue, Lei Chang, Xuena Zhu, Wenjun Liu, Tingbo Liang   +5 more
wiley   +1 more source

Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination Strategies

Journal of Cellular and Molecular Medicine, Volume 29, Issue 16, August 2025.
ABSTRACT Synthetic lethality (SL) not only addresses the challenge of drug resistance associated with classical targeted therapies but also offers innovative therapeutic approaches for previously ‘undruggable’ targets, such as deletion mutations in tumour suppressor genes.
Lingya Wu, Yixuan Deng, Zhe Lei, Yuhong Wang, Shan Huang   +4 more
wiley   +1 more source

Novel clinical trial designs emerging from the molecular reclassification of cancer

CA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.
Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam, Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock   +4 more
wiley   +1 more source

Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital‐Based Towards Home‐Sampling

Biomedical Chromatography, Volume 39, Issue 5, May 2025.
ABSTRACT Home‐sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital‐based sampling methods, though it presents challenges. This review aims to summarize the state‐of‐the‐art of home‐sampling methods for TDM and evaluates the analytical and clinical validation challenges.
Marinda Meertens, Hilde Rosing, Neeltje Steeghs, Jos H. Beijnen, Alwin D. R. Huitema   +4 more
wiley   +1 more source